

10/010,749

Attorney Docket No. 21349/14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

APPLICANT:

Jean-Louis Escary

APR 0 0 2002

APPLICATION NO.: 10/010,749

GROUP ART UNIT: 165 TECH CENTER 1600/2900

FILED:

December 6, 2001

EXAMINER: Unknown

FOR:

Method for the Determination of at Least One Functional Polymorphism

In the Nucleotide Sequence of a Preselected Candidate Gene and Its Applications

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the. Assistant Commissioner of Patents, Washington, D.C. 20231 on

Deborah Celeste

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant hereby submits an Information Disclosure Statement for consideration by the Examiner.

10/010,749



RECEIVED

I. <u>LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION</u> 5 2002

TECH CENTER 1600/2000 The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

a. X Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

a. <u>X</u>	Except as may be indicated below in (b), all of the patents, publications
	or other information are in the English language or were cited in an
	English language Search Report, a copy of which is attached hereto
	(concise explanation not required).
b	A concise explanation of the relevance of all patents, publications or other
	information listed that is not in the English language is as follows:
c	The following additional information is provided for the Examiner's
	consideration:

FEES

IV.	THIS IDS I	S BEING FILED UNDER 37 C.F.R. § 1.97(b)				
	(check one	box)				
	a	within three months of the filing date of a national application (37 C.F.R.				
		§ 1.97(b) (1)). No fee or certification is required.				
	b	within three months of the date of entry of the national stage as set forth				
		in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.				
	c. <u>X</u>	before the mailing date of a first Action on the merits (37 C.F.R. §				
		1.97(b) (3)). No fee or certification is required. In the event that a first				
		Office Action on the merits has been issued, please consider this IDS				
		under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. §				
		1.97(e)below, or, if no certification has been made, charge our deposit				
		account a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).				
V.	THIS IDS I	S BEING FILED UNDER 37 C.F.R. § 1.97(c):				
	(check one	box)				
	before the r	nailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. §				
	1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311					
	(See 37 C.F.R. § 1.97(c) (2)).					
	a	No certification; therefore, a fee in the amount of \$180.00 is required by				
		37 C.F.R § 1.17(p).				
		or				
	b	See the certification below. No fee is required.				

VI. <u>CERTIFICATION UNDER 37 C.F.R. § 1.97(e)</u> (check <u>only</u> one box)

The undersigned hereby certifies that

a.	each item of information contained in the IDS was cited in a	
	communication from a foreign Patent Office in a counterpart foreign	
	application not more than three months prior to the filing of this IDS; or	
b	no item of information contained in the IDS was cited in a communication	on
	from a foreign Patent Office in a counterpart foreign application or, to th	ıe
	best of my knowledge after making reasonable inquiry, was known to an	ıy
	individual designated in 37 C.F.R. § 1.56(c) more than three months prior	r
	to the filing of this statement.	
c.	Some of the items of information were cited in a communication from a	
	foreign Patent Office. As to this information, the undersigned certifies	
	that each item of information contained in the IDS was cited in a	
	communication from a foreign Patent Office in a counterpart foreign	
	application not more than three months prior to the filing of this IDS. As	s
	to the remaining information, the undersigned hereby certifies that no	
	item of this remaining information contained in the IDS was cited in a	
	communication from a foreign Patent Office in a counterpart foreign	
	application or, to the best of my knowledge after making reasonable	
	inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c)	
	more than three months prior to the filing of this statement.	
	Places shares Denosit Assessmt No. 500260 in the amount of \$180.00 for the	
	Please charge Deposit Account No. 500369 in the amount of \$180.00 for the	
	above-indicated fee. A triplicate copy of this paper is attached.	
<u>X_</u>	No fee is required.	

VII. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.704(d) (PATENT TERM ADJUSTMENT)

Applies to original applications (other than design) filed on or after May 29, 2000

[]	Each item of information contained in the Information Disclosure Statement was cited in						
	a communication from a foreign patent office in a counterpart application and this						
	comm	unication was not received by any individual designated in § 1.56(c) more than					
	thirty	days prior to the filing of the Information Disclosure Statement.					
[X]	Enclos	sed herewith is form PTO-1449:					
	[X]	Copies of the cited references are enclosed.					
	[]	Copies of cited references are enclosed except those entered in prior					
		application, U.S. Application No. [], to which priority under 35 U.S.C. 120					
		is claimed. [The earlier application contains copies of the cited references.]					
	[]	The listed references were cited in the enclosed International Search Report in a					
		counterpart foreign application.					
	[]	The "concise explanation" requirement (non-English references) for reference(s)					
		[] under 37 CFR 1.98(a)(3) is satisfied by:					
		[] the explanation provided on the attached sheet					
		[] the explanation provided in the Specification.					
		[] submission of the enclosed International Search Report.					
		[] the enclosed English language abstract.					

10/010,749

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 500369.

Respectfully submitted,

Date: March 29, 2002

Jamce L. Kugler, Esq. Registration No. 50,429 Customer No. 21710

Brown Rudnick Berlack Israels, LLP

One Financial Center Boston, MA 02111 Tel: (617) 856-8290

#1098863 - 21349/5



Sheet 1 of 2

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY DOCKET NO. SERIAL NO. 21349/5 10/010,749							
					APPLICANT(S): Escary, JL					
					FILING DATE: ART UNIT: December 6, 2001 1651						
				UNITED STATE	S PATENT DO	CUMENTS					
· EXAM. INITIAL		DOCUMENT NUMBER		DATE	INV	ENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR		
	A1	5,7	795,976	1998-08-18	l .	ner, et al	536	25.4	1995-08-08		
		Y		FOREIGN P.	ATENT DOCU	MENTS	·		·		
		DOCUME	ENT NUMBER	DATE	СО	UNTRY	CLASS	SUB CLASS	TRAN Y/N		
	B1	WO 0066772		2000-11-09		PCT		1/68	Abstract only		
	B2	wo	0034652	2000-06-15		РСТ	F04B	1/14,1/12	Y		
	вз,	WO 01/27857		2001-04-19		PCT	G06F	19/00	Y		
	B4	EP 0 626 448 A		1994-11-30		ЕРО	C12N	15/21	N		
	B5	WO 98 00541 EP 0 658 627 A2 EP 0 095 702 A1 WO 83/02461		1998 -01-08		PCT	C12N	15/12	Y		
	В6			1995-06-21		ЕРО	C12N	15/85	Y		
	В7			1983-05-24		ЕРО	C12N	15/00	N		
	B8			1983-07-21		PCT	C12N	15/00	Y		
	B9 WO 99/57292		1999-11-11		PCT	C12N	15/90	Y			
		OTHER I	DOCUMENTS (INCLUDING AU	THOR, TITLE,	DATE, PERTINE	NT PAGES, E	TC.)			
		C1	1	terferon-α ₂ Var : 341-349 (1995		ıman Genome. J	. Interferon a	and Cytok	ine		
•						Rare Allelic Variants of the Interferon-α ₂ Gene in Human n and Cytokine Research 15: 403-406 (1995).					
	C3 Kita et al., Determination of interferon-α ₂ allele composition in the genomic DNA from healthy volunteers and leukemic patients in Japan. J. Interferon and Cytokine Research 17:135-140. (1997).							•			
Examiner:						Date:					

Sheet 2 of 2

FORM PTO-1449 TOEMARK OF INFORMATION DISCLOSURE STATEMENT				ATTY DOCKET NO. SERIAL NO. 21349/5 10/010,749			
				APPLICANT(S): Escary, JL			
				FILING DATE: December 6, 2001	EIVE	PT UNIT:	:
			UNITED STATE	ES PATENT DOCUMENTS	<u> </u>		
EXAM. INITIAL	DOCUMENT NUMBER		DATE	INVENTOR	NTEH 1600	SUB SUB	FIL. DATE IF APPR
	ı	i	FOREIGN P	ATENT DOCUMENTS	qi (i a a a a a a a a a a a a a a a a a		
	DOCUM	ENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
	OTHER	DOCUMENTS (INCLUDING AU	THOR, TITLE, DATE, PERTINE	NT PAGES, E	ГС.)	
	C4	2000: Third	international mo	leotide Polymorphism Identificate the street of the street			
	Rodi, C. The Human Genome Project and Human Variation – Determination of Alle Frequencies Using Pooled Samples and Massarray MALDI-TOF MS. SNP 2000: The international meeting on single nucleotide polymorphism and complex genome analy Human mutation 17:340 Abst. 91 (2001).						Third
	C6	International		Map of the Human Genome, Mun Mutations in the Human Genote. p. 26 (2001).			
	C7			expression of human interferon- Biochem. J., Japanese Biochem.			
	C8 Bolk, S. et al., High-Throughput SNP Genotyping using Single-base Extension. Am Hum. Gen. 65(4): A97 (1999).						Am. J.
	C9	Karayianni-Vasconselos, G. et al., Comparison of Antigenic Properties of Three Interferon (IFN)-Alpha2 Subvariants and Establishment of a Quantitative IFN-alpha2 ELISA. Acta Virol. 37:509-514 (1993).					
	C10		an, "Approach chool of Medic	tes to Allele Frequency Determinine, pp. 1-5.	nation," Wa	shington	
	C11	International	Search Report	of France, pp. 1-6.			
Examiner:		-		Date:			